Literature DB >> 12738640

Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine.

Inna G Ovsyannikova1, Neelam Dhiman, Robert M Jacobson, Robert A Vierkant, Gregory A Poland.   

Abstract

The protective effect of measles immunization is due to humoral and cell-mediated immune responses. Little is known about cell-mediated immunity (CMI) to measles vaccine virus, the relative contribution of CD4(+) and CD8(+) T cells to variability in such immune responses, and the immunologic longevity of the CMI after measles vaccination in humans. Our study characterizes cellular immune response in subjects seronegative or highly seropositive for measles vaccine immunoglobulin G-specific antibody, aged 15 to 25 years, previously immunized with two doses of measles-mumps-rubella II vaccine. We evaluated the ability of subjects to respond to measles vaccine virus by measuring measles virus-specific T-cell proliferation. We examined the frequencies of measles virus-specific memory Th1 and Th2 cells by an ELISPOT assay. Our results demonstrated that proliferation of T cells in seronegative subjects was significantly lower than that for highly seropositive subjects (P = 0.003). Gamma interferon (IFN-gamma) secretion predominated over interleukin 4 (IL-4) secretion in response to measles virus in both groups. The median frequency of measles virus-reactive CD8(+) T cells secreting IFN-gamma was 0.09% in seronegative subjects and 0.43% in highly seropositive subjects (P = 0.04). The median frequency of CD4(+) T cells secreting IL-4 in response to measles virus was 0.03% in seronegative subjects and 0.09% in highly seropositive subjects (P = 0.005). These data confirm the presence of measles virus-specific cellular immune responses post-measles vaccine immunization in humans. The detection of measles virus-induced IFN-gamma and IL-4 production by ELISPOT can be used to identify measles virus-specific low-frequency memory T cells in subjects immunized with measles vaccine. These differences agree in directionality with the observed antibody response phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738640      PMCID: PMC154970          DOI: 10.1128/cdli.10.3.411-416.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  33 in total

Review 1.  New methods for assessing T-cell responses.

Authors:  N Bercovici; M T Duffour; S Agrawal; M Salcedo; J P Abastado
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

2.  Secondary failure rates of measles vaccines: a metaanalysis of published studies.

Authors:  J F Anders; R M Jacobson; G A Poland; S J Jacobsen; P C Wollan
Journal:  Pediatr Infect Dis J       Date:  1996-01       Impact factor: 2.129

3.  Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines.

Authors:  V A de Souza; C S Pannuti; L M Sumita; H F de Andrade Júnior
Journal:  J Med Virol       Date:  1997-07       Impact factor: 2.327

Review 4.  Single cell analyses of cytokine production.

Authors:  L L Carter; S L Swain
Journal:  Curr Opin Immunol       Date:  1997-04       Impact factor: 7.486

5.  Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination.

Authors:  N Bautista-López; B J Ward; E Mills; D McCormick; N Martel; S Ratnam
Journal:  Vaccine       Date:  2000-01-31       Impact factor: 3.641

6.  Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal.

Authors:  B Samb; P Aaby; H C Whittle; A M Seck; S Rahman; J Bennett; L Markowitz; F Simondon
Journal:  Pediatr Infect Dis J       Date:  1995-03       Impact factor: 2.129

7.  A novel sensitive approach for frequency analysis of measles virus-specific memory T-lymphocytes in healthy adults with a childhood history of natural measles.

Authors:  R Nanan; A Rauch; E Kämpgen; S Niewiesk; H W Kreth
Journal:  J Gen Virol       Date:  2000-05       Impact factor: 3.891

8.  Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.

Authors:  B J Ward; N Boulianne; S Ratnam; M C Guiot; M Couillard; G De Serres
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

9.  Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children.

Authors:  A Jaye; A F Magnusen; A D Sadiq; T Corrah; H C Whittle
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

10.  Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody.

Authors:  S Ratnam; V Gadag; R West; J Burris; E Oates; F Stead; N Bouilianne
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

View more
  33 in total

1.  Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen.

Authors:  Patricia O Viana; Erika Ono; Maristela Miyamoto; Reinaldo Salomao; Beatriz T Costa-Carvalho; Lily Y Weckx; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

2.  HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Jenna E Ryan; Robert A Vierkant; V Shane Pankratz; Steven J Jacobsen; Gregory A Poland
Journal:  Immunogenetics       Date:  2005-01-27       Impact factor: 2.846

3.  Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination.

Authors:  N Dhiman; I G Ovsyannikova; J E Ryan; R M Jacobson; R A Vierkant; V S Pankratz; S J Jacobsen; G A Poland
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 4.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

5.  Human leukocyte antigen associations with humoral and cellular immunity following a second dose of measles-containing vaccine: persistence, dampening, and extinction of associations found after a first dose.

Authors:  Robert M Jacobson; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  Vaccine       Date:  2011-08-26       Impact factor: 3.641

Review 6.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

7.  Induction of CD4 T cell proliferation and in vitro Th1-like cytokine responses to measles virus.

Authors:  R C Howe; N Dhiman; I G Ovsyannikova; G A Poland
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

8.  Cytokines expression profile and kinetics of Peste des petits ruminants virus antigen and antibody in infected and vaccinated goats.

Authors:  Arun Patel; Kaushal Kishor Rajak; Vinayagamurthy Balamurugan; Arnab Sen; Shashi Bhusan Sudhakar; Veerakyathappa Bhanuprakash; Raj Kumar Singh; Awadh Bihari Pandey
Journal:  Virol Sin       Date:  2012-07-28       Impact factor: 4.327

9.  Importance of HLA-DQ and HLA-DP polymorphisms in cytokine responses to naturally processed HLA-DR-derived measles virus peptides.

Authors:  Inna G Ovsyannikova; Robert A Vierkant; Gregory A Poland
Journal:  Vaccine       Date:  2006-05-03       Impact factor: 3.641

10.  Development of an artificial-antigen-presenting-cell-based assay for the detection of low-frequency virus-specific CD8(+) T cells in whole blood, with application for measles virus.

Authors:  Zaza M Ndhlovu; Monika Angenendt; Diana Heckel; Jonathan P Schneck; Diane E Griffin; Mathias Oelke
Journal:  Clin Vaccine Immunol       Date:  2009-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.